13 Common Errors in Psychopharmacology





Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008; 9(9):1451-62.

Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci 2014; 68(1):37-49.

Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, et al. Neuroleptic drug exposure and treatment of Parkinsonism in the elderly – a case-control study. Am J Med 1995; 99(1):48-54.

Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004; 161(1):116-24.

Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007; 12(3):232-46.

Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DG, Bourne RC, et al. Adverse-Effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 1983; 13(3):513-27.

Buhrich N, Weller A, Kevans P. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatric Serv 2000; 51(7):928-9.

World Health Organization heads of centers collaborating in WHO coordinated studies on biological aspects of mental illness. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. Br J Psychiatry 1990; 156:412.

World Health Organization. [Internet] Role of anticholinergic medications in patients requiring long-term antipsychotic treatment for psychotic disorders. 2012; Available from: http://www.who.int/mental_health/mhgap/evidence/resource/psychosis_q6.pdf [cited 2015 Nov 25]

Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 2012; 26(9):1167-74.

Ahmad S. Anticholinergics and amantadine. In: Sadock BJ, Sadock VA, Ruiz P, editors. Comprehensive Textbook of Psychiatry, 9th ed. Philadelphia: Lippincott William and Wilkins; 2009. pp. 3014-21.

Avorn J, Bohn RL, Mogun H, Gurwitz JH, Monane M, Everitt D, et al. Neuroleptic drug exposure and treatment of Parkinsonism in the elderly: a case-control study. Am J Med 1995; 99(1):48-54.

Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome – clinical-features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988; 51(6):850-4.

Raja M, Raja S. Clozapine safety, 40 years later. Curr Drug Saf 2014; 9(3):163-95.

Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55(suppl B):137–8.

Drew L. Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry 2013; 21(4):335-7.

Grover S, Dutt A, Avasthi A. Indian research: Focus on clozapine. Indian J Psychiatry 2010; 52(2):168–73.

Chand M. A prospective study of use of clozapine in treatment resistant schizophrenia. Indian J Psychiatry 2001; 43:98.

Jagadheesan K, Agarwal SK, Nizamie SH. Clozapine-induced thrombocytopenia: a pilot study. Hong Kong J Psychiatry 2003; 13:12–5.

Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006; 40(4):683-8.

Kristiansen JE, Dastidar SG, Palchoudhuri S, Roy DS, Das S, Hendricks O, et al. Phenothiazines as a solution for multidrug resistant tuberculosis: From the origin to present. Int Microbiol 2015; 18(1):1-12.

Meng Q, Sun X, Wang J, Wang Y. [Mechanism of thioridazine plus medroxyprogesterone in the treatment of endometrial cancer]. Zhonghua Yi Xue Za Zhi 2015; 95(19):1540-3. [Abstract]

Lu M, Li J, Luo Z, Zhang S, Xue S, Wang K, et al. Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis. Onco Targets Ther 2015; 8:1543-52.

Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas SH, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. Clin Pharmacol Ther 2015; doi: 10.1002/cpt.250. [Epub ahead of print]

Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54(1):1-13.

Menkes DB, Knight JC. Cardiotoxicity and prescription of thioridazine in New Zealand. Aust N Z J Psychiatry 2002; 36(4):492-8.

Shankar R. Health ministry once again to ban FDC of flupenthixol + melitracen. [updated 26 Dec 2013; cited 25 Nov 2015] Available from: http://www.pharmabiz.com/NewsDetails.aspx?aid=79454&sid=1

Fritze J, Spreda I. Tolerability of low dose neuroleptics: a case control study of flupenthixol. Eur Neuropsychopharmacol 1997; 7(4):261-6.

Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67(9):1327-40.

Steenen SA, van Wijk AJ, van der Heijden GJ, van Westrhenen R, de Lange J, de Jongh AJ. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. Psychopharmacol 2015; pii: 0269881115612236. [Epub ahead of print]

Taylor D, Paton C, Kapur S. SSRIs and bleeding. In: The Maudsley prescribing guidelines in Psychiatry, 12th ed. West Sussex: Wiley Blackwell; 2015. pp 328-31.

Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71(12):1565-75.

Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a population-based cohort study. Arch Intern Med 2003; 163:59-64.

Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ 2005; 331:529-30.

Tylee A, Dickens C, Chew-Graham C. Primary Care Guidance: Treating Depression in People with Coronary Heart Disease (CHD) – 2014 update; Royal College of General Practitioners & Royal College of Psychiatrists; 2014. Available from: http://www.rcgp.org.uk/clinical-and-research/a-to-z-clinical-resources/~/media/Files/CIRC/Mental%20Health%20-%202014/7%20Treating%20depression%20in%20people%20with%20coronary%20heart%20disease%202014.ashx [cited 2015 Nov 25]

Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008; 118(6):434-42.

Ramamurthy G, Trejo E, Faraone SV. Depression treatment in patients with coronary artery disease: a systematic review. Prim Care Companion CNS Disord 2013; 15(5). pii: PCC.13r01509. doi: 10.4088/PCC.13r01509.

Summers KM, Martin KE, Watson K. Impact and clinical management of depression in patients with coronary artery disease. Pharmacotherapy 2010; 30(3):304-22.

UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361(9360):799-808.

Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005; (2):CD000076.

Luchini F, Medda P, Mariani MG, Mauri M, Toni C, Perugi G. Electroconvulsive therapy in catatonic patients: Efficacy and predictors of response. World J Psychiatry 2015; 5(2):182-92.

Gangadhar BN, Phutane VH, Thirthalli J. Research on electroconvulsive therapy in India: An overview. Indian J Psychiatry 2010; 52(Suppl1):S362–5.

McFarquhar TF, Thompson J. Knowledge and attitudes regarding electroconvulsive therapy among medical students and the general public. J ECT 2008; 24(4):244-53.

Dowman J, Patel A, Rajput K. Electroconvulsive therapy: attitudes and misconceptions. J ECT 2005; 21(2):84-7.

Poster E, Baxter LR Jr, Hammon CL. Nursing students' perception of electroconvulsive therapy: Impact of instruction with an electroconvulsive therapy videotape. Convuls Ther 1985; 1(4):277-82.

Guze BH, Baxter LR Jr, Liston EH, Roy-Byrne P. Attorneys' perceptions of electroconvulsive therapy: impact of instruction with an ECT videotape demonstration. Compr Psychiatry 1988; 29(5):520-2.

Chavan BS, Kumar S, Arun P, Bala C, Singh T. ECT: Knowledge and attitude among patients and their relatives. Indian J Psychiatry 2006; 48:34–8.

Ramachandra, Gangadhar BN, Lalitha N, Janakiramaiah N, Shivananda BL. Patients' knowledge about ECT. NIMHANS Journal 1992; 10:27–31.

Agarwal AK, Andrade C. Indian psychiatrists' attitudes towards Electroconvulsive Therapy. Indian J Psychiatry 1997; 39:54–60.

Hillbom M, Pieninkeroinen I, Leone M. Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. CNS Drugs 2003; 17(14):1013-30.

Bråthen G, Ben-Menachem E, Brodtkorb E, Galvin R, Garcia-Monco JC, Halasz P, et al. Alcohol - related seizures. In: Gilhus NE, Barnes MP, Brainin M, editors. European Handbook of Neurological Management: 2nd ed. West Sussex: Blackwell Publishing; 2011. pp 429-36. Available from: http://www.eaneurology.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2011_Alcohol-related_seizures.pdf

Bråthen G, Ben-Menachem E, Brodtkorb E, Galvin R, Garcia-Monco JC, Halasz P, et al . EFNS Guideline on the diagnosis and management of alcohol - related seizures: report of an EFNS task force. Eur J Neurol 2005; 12:575-81.

Rogawski MA. Update on the neurobiology of alcohol withdrawal seizures. Epilepsy Curr 2005; 5(6):225–30.

Macdonald RL, McLean MJ. Anticonvulsant drugs: mechanisms of action. Adv Neurol 1986; 44:713-36.

World Health Organization. [Internet] Management of alcohol withdrawal. 2012; [cited 2015 Nov 25] Available from: http://www.who.int/mental_health/mhgap/evidence/alcohol/q2/en/

Kattimani S, Bharadwaj, B. Clinical management of alcohol withdrawal: A systematic review. Ind Psychiatry J 2013; 22(2):100–8.

Lejoyeux M, Solomon J, Adès J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998; 33(6):563-75.

Sellers E, Ciraulo DA. DuPont RL, Griffiths RR. Kosten TR, Romach, MK, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry 1993; 54 (Suppl. 10):64-75.

Kolla BP, Mansukhani MP, Schneekloth T. Pharmacological treatment of insomnia in alcohol recovery: a systematic review. Alcohol Alcohol 2011; 46(5):578-85.

Brower KJ. Assessment and treatment of insomnia in adult patients with alcohol use disorders. Alcohol 2015; 49(4):417-27.

Oei TP, Loveday WA. Management of co-morbid anxiety and alcohol disorders: parallel treatment of disorders. Drug Alcohol Rev 1997; 16(3):261-74.

Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev 2015;1:CD007505.

Wyszynski AA. The Patient with Hepatic Disease, Alcohol Dependence, and Altered Mental Status. In: Wyszynski AA, Wyszynski B, editors, Manual of Psychiatric Care for the Medically Ill. Washington: American Psychiatric Publishing; 2005. pp 27-47.

Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 2014; 9(2):e87366.

Fuller RK, Gordis, E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004; 99:21–4.

de Sousa A, de Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2005; 40(6):545-8.

De Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 2004; 39(6):528-31.

De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 2008; 34(4):460-3.

Abraham J, Chandrasekaran R, Chitralekha V. A prospective study of treatment outcome in alcohol dependence from a deaddiction center in India. Indian J Psychiatry 1997; 39(1):18-23.

Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20(5):427-35.

Brewer C. Disulfiram for alcohol abuse: Why is such an effective drug so under-prescribed? Primary Care in the New NHS 2001; 227–31.

Alharbi FF, el-Guebaly N. The relative safety of disulfiram. Addict Disord Their Treatment 2013; 12:140–7.

Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007; 4:CD003620.

The Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol 2013; 19(3):216–54.

European Association for the Study of the Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57:399–420.

O'Shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010; 51(1):307-28.